GUFICBIOPharmaceuticals
Gufic Biosciences Ltd — PE Ratio & Valuation Analysis
₹273.80
-4.82%
Current P/E64.59xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E42.8x51.0% above avg
⚠️
103.3% Premium to Industry
GUFICBIO P/E 64.59x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹6.95 | ₹336 | 48.3x |
| 2024 | ₹8.74 | ₹455 | 52.1x |
| 2023 | ₹8.22 | ₹316 | 38.5x |
| 2022 | ₹9.89 | ₹226 | 22.9x |
| 2021 | ₹4.56 | ₹238 | 52.1x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Gufic Biosciences Ltd Valuation
Gufic Biosciences Ltd (GUFICBIO) currently trades at 64.59x earnings. The Pharmaceuticals sector average PE is 31.77x. GUFICBIO commands a premium, reflecting high growth expectations. Historically, GUFICBIO has traded at an average PE of 42.8x — it is currently above that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
12.32%
Dividend Yield
0.03%
More on Gufic Biosciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.